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our findings in tgAPP mice, soluble A  induced mitochon-
drial dysfunction in brain cells from tau transgenic mice. 
 Conclusion: Our results indicate that mitochondrial dys-
function is exacerbated by the presence of soluble A  spe-
cies as a very early event during pathogenesis. 
 Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Alzheimer’s disease (AD) is the most frequent form of 
dementia among the elderly and is characterized by the 
neuropathological hallmarks of extracellular amyloid 
plaques and intracellular neurofibrillary tangles in the 
brain of AD patients. Amyloid plaques are composed of 
the   -amyloid (A  ) protein, derived from its precursor 
protein APP. Neurofibrillary lesions are formed from 
paired helical filaments composed of hyperphosphory-
lated tau protein, a microtubule-associated protein.
 In recent years, attempts have been undertaken to 
identify the toxic species of A  . The focus of attention has 
since shifted from fibrillar to oligomeric species of A  as 
the large, insoluble A  deposits which form the amyloid 
plaques in the limbic and association cortices of AD pa-
tients are in equilibrium with small, diffusible oligomers 
of the peptide that appear capable of interfering with hip-
pocampal synaptic function and memory  [1, 2] . In addi-
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 Abstract 
 Background: Mitochondrial dysfunction has been identi-
fied in neurodegenerative disorders including Alzheimer’s 
disease, where accumulation of   -amyloid (A  ) and oxida-
tive stress seem to play central roles in the pathogenesis, by 
probably directly leading to mitochondrial dysfunction.  Ob-
jective: In order to study the in vivo effect of A  load during 
aging, we evaluated the mitochondrial function of brain 
cells from transgenic mice bearing either mutant amyloid 
precursor protein (tgAPP) or mutant amyloid precursor pro-
tein and mutant PS1 (tgAPP/PS1) as well as from nontrans-
genic wild-type littermates. tgAPP mice exhibit onset of A  
plaques at an age of 6 months, but the intracellular soluble 
A  load is already increased at 3 months of age. In contrast, 
onset of A  plaques starts at an age of 3 months in tgAPP/
PS1 mice. In addition, we investigated the effects of different 
A  preparations on mitochondrial function of brain cells 
from tau transgenic mice.  Results: Of note, mitochondrial 
damage such as reduced mitochondrial membrane poten-
tial and ATP levels can already be detected in the brains from 
these mice before the onset of plaques. In agreement with 
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tion, mitochondrial dysfunction and energy metabolism 
deficiencies are recognized as earliest events and corre-
lated with impairments of cognitive abilities in AD  [3–6] . 
Nevertheless, the specific mechanisms leading to mito-
chondrial failure in AD are not well understood.
 In order to elucidate the impact of A  during the 
course of AD pathogenesis in vivo, we investigated the 
brains from APP transgenic animals before and at the age 
of onset of A  plaques. Moreover, we previously provided 
evidence for a mitochondrial dysfunction in P301L tau 
transgenic mice, a strain modelling the tau pathology of 
AD  [7] . In light of recent studies suggesting that soluble 
rather than fibrillar aggregated A  might be the actual 
toxic species, the toxicity of different preparations of A  
is currently under investigation.
 Methods 
 C57BL/6 mice aged 3 months bearing the human Swedish 
(KM595/596NL) and London (V717I) mutations in the 751-ami-
no-acid form of the human amyloid precursor protein (tgAPP) 
under the control of a murine Thy-1 promoter, 3-month-old 
tgAPP/PS1 mutant mice [by crossing the tgAPP mice with HMG-
CoA reductase promoter-driven PS1 (M146L) transgenic mice], 
as well as age-matched nontransgenic wild-type (WT) littermates 
were used for the experiments  [8, 9] . The tgAPP mice exhibit on-
set of A  plaques at an age of 6 months, but the intracellular sol-
uble A  load is already detectable at 3 months of age  [8, 10] , 
whereas in tgAPP/PS1 mice plaque onset starts at an age of 3 
months  [10, 11] . The tau transgenic mice express the human 
pathogenic mutation P301L of tau together with the longest hu-
man brain tau isoform (htau40) under the control of the neuron-
specific murine Thy-1.2 promoter  [12, 13] . P301L tau mice show 
tau hyperphosphorylation already at 3 months. Neurofibrillary 
tangle formation starts at 6 months of age. The mice were ana-
lyzed at 13–15 months of age. Cortical brain cell preparation, de-
termination of mitochondrial membrane potential, and determi-
nation of ATP levels were obtained as previously described  [7] . 
Soluble A  42 preparations were performed according to Gong-
hard and coworkers  [14] .
 Results and Conclusions 
 To further clarify the synergistic effects of aging and 
A  pathology, we investigated mitochondrial function of 
cortical brain cells from transgenic mice (tgAPP and 
tgAPP/PS1) and WT mice. Of note, pronounced mito-
chondrial dysfunction in adult tgAPP mice, such as a 
drop in mitochondrial membrane potential ( fig. 1 a) and 
reduced ATP levels ( fig. 1 b), already appeared at 3 months 
when elevated A  levels but not yet A  -containing 
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 Fig. 1.  a Decreased mitochondrial membrane potential in cortical 
brain cells from transgenic mice. Mitochondrial membrane po-
tential in brain cells from 3-month-old tgAPP and tgAPP/PS1 
mice after 4 h of in vitro incubation was significantly reduced 
compared to WT mice. Data are presented as a box-and-whisker 
graph: the box extends from the 25th percentile to the 75th per-
centile, with a line at the median, the whiskers extend above and 
below the box to show the highest and lowest values [n = 4–6; me-
dian: 294,500 (WT), 234,580 (tgAPP), and 175,365 (tgAPP/PS1) 
R123 fluorescence units/mg]. One-way ANOVA (p = 0.001) fol-
lowed by Tukey’s post hoc test:  * p  ! 0.05,  * * p  ! 0.01 versus WT 
mice.  b Reduced ATP levels in transgenic mice. Levels of ATP in 
cortical brain cells of 3-month-old non-tgAPP, tgAPP and tgAPP/
PS1 mice after 4 h of in vitro incubation were significantly re-
duced compared to WT mice. Data are presented as a box-and-
whisker graph [n = 4–6; median: 96.8% (WT), 75.49% (tgAPP), 
and 29.45% (tgAPP/PS1) of control]. One-way ANOVA (p  ! 0.001) 
followed by Tukey’s post hoc test:  * * * p  ! 0.001 versus tgAPP and 
WT mice,  * p  ! 0.05 versus WT mice. 
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plaques are present. In tgAPP/PS1 mice with a high A  
load exhibiting A  plaques already at an age of 3 months, 
the strongest reductions in mitochondrial membrane 
 potential and ATP levels were found ( fig. 1 a, b). We con-
clude that A  -depending mitochondrial dysfunction 
starts already at a very young age and accelerates substan-
tially with increasing age and A  load as well as accumu-
lation.
 In addition, we determined whether soluble A  42 
would exert a more pronounced toxicity towards P301L 
tau transgenic mitochondria when compared to fibrillar 
A  . Interestingly, our preliminary results indicate that 
oligomeric and fibrillar A  42 caused a similar decrease in 
mitochondrial membrane potential in cortical brain cells 
obtained from P301L tau transgenic mice (data not 
shown) suggesting that in developing treatment strate-
gies, it may not be sufficient to target either oligomeric or 
fibrillar A  species, but that the best approach is either to 
prevent formation of excess A  at all or to assist in its 
rapid clearance. Rigorous scientific research has identi-
fied multiple interactive mechanisms that parallel and 
are likely causative for the development of AD. Evidence 
is provided that AD is triggered by soluble, neurotoxic 
assemblies of A  , while the late-stage pathology land-
marks of amyloid plaques and tangles potentiate toxicity 
by driving a vicious cycle of A  generation and oxidation, 
mitochondrial damage, glucose hypometabolism, energy 
deficiency, each accelerating the other, since a deficiency 
in energy can, in turn, induce BACE1 activation leading 
to an increased production of A   [15] .
 Although the advancement in our understanding of 
the molecular mechanisms of AD has resulted in a dra-
matic enhancement of our ability to diagnose and treat 
the disorder, there is still a constant need for the identifi-
cation of AD-specific abnormalities finally leading to 
neurodegeneration, which might open new ways for the 
development of more efficacious therapies. Based on this 
assumption, strategies involving efforts to protect cells at 
the mitochondrial level by stabilizing or restoring mito-
chondrial function or to interfere with the energy me-
tabolism appear to be promising in preventing AD, be-
sides strategies with regard to the treatment and/or re-
moval of both A  and tau pathology.
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